Rapamycin inhibits the proliferation of prostate cancer cell line 22RV1 and activity of S6K1 / 中华男科学杂志

<p><b>OBJECTIVE</b>To explore the effects of rapamycin on the proliferation of prostate cancer cell line 22RV1 and the activity of S6K1.</p><p><b>METHODS</b>Prostate cancer 22RV1 cells cultured in vitro were treated with rapamycin at the concentrations of 0, 50, 100, 200 and 400 nmol/L. The inhibition rate of the cells'proliferation was detected by MTT, and the activity of S6K1 was determined by liquid scintillation counting.</p><p><b>RESULTS</b>Rapamycin significantly inhibited the proliferation of the prostate cancer 22RV1 cells and the activity of S6K1 in a dose- dependent manner, most obviously at 400 nmol/L (P<0.01).</p><p><b>CONCLUSION</b>Rapamycin can effectively suppress the proliferation of prostate cancer 22RV1 cells by regulating the expression of S6K1, the downstream protein of mammalian target of rapamycin (mTOR).</p>

A retrospective study of 4865 cases of paroxysmal supraventricular tachycardia treated with catheter ablation / 生物医学工程学杂志

In recent 10 years, using radiofrequency catheter ablation, our medical center has treated 4865 cases of paroxysmal supraventricular tachycardia (PSVT). To improve clinical practice, a retrospective analysis of this group was made. In this group, 2092 cases were atrioventricular reentry tachycardia (AVRT), including 1415 left accesory pathway and 677 right accesory pathway, and 2773 cases were atrioventricular nodal reentry tachycardia (AVNRT). The total success rate of radiofrequency treatment is 99.71%; the recurrence rate after half a year 1.73%; the total complication rate 1.25%. In conclusion, radiofrequency ablation is a safe and effective treatment for tachycardia with high rate of success and low rate of complication.